𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression

✍ Scribed by Andrew F. Leuchter; Melinda Morgan; Ian A. Cook; Jennifer Dunkin; Michelle Abrams; Elise Witte


Publisher
Springer
Year
2004
Tongue
English
Weight
162 KB
Volume
177
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Does elimination of placebo responders i
✍ Sandra Lee; John R. Walker; Laura Jakul; Kathryn Sexton πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 109 KB

The use of a placebo run-in phase, in which placebo responders are withdrawn from a study before random assignment to treatment condition, has been criticized as favoring the active treatment in clinical trials. We compared the effect size of randomized, placebo-controlled clinical trials (in the tr

Safety and tolerability of duloxetine in
✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 185 KB πŸ‘ 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random

Rational emotive behavior therapy, cogni
✍ Daniel David; Aurora Szentagotai; Viorel Lupu; Doina Cosman πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 169 KB πŸ‘ 2 views

## Abstract A randomized clinical trial was undertaken to investigate the relative efficacy of rational‐emotive behavior therapy (REBT), cognitive therapy (CT), and pharmacotherapy in the treatment of 170 outpatients with nonpsychotic major depressive disorder. The patients were randomly assigned t